CO-NEWMONT
1.6.2020 15:02:10 CEST | Business Wire | Press release
Newmont Corporation (NYSE: NEM, TSX: NGT) (Newmont or The Company) today announced the publication of its 2019 Sustainability Report, Beyond the Mine , a transparent and comprehensive disclosure of the Company’s environmental, social and governance (ESG) performance.
“Our sustainability report provides investors and other stakeholders a transparent and detailed look at look at our safety, environmental and social performance,” said Tom Palmer, President and Chief Executive Officer. “In 2019, we completed two transformative transactions whilst enhancing our ESG performance to align with our position as the world’s leading gold company.”
Newmont’s 2019 sustainability highlights include:
- Achieving no workplace fatalities and conducting a global safety culture review, which identified several opportunities to enhance Newmont’s Fatality Risk Management program and improve the way fatality risks are managed
- Further strengthening management of tailings, whilst enhancing transparency through a new tailings website with details on all 104 tailings dam facilities at Newmont’s operating sites, joint ventures, subsidiaries and legacy sites
- Reducing greenhouse gas emissions intensity by 13.7 percent, compared to the 2013 baseline, which achieves approximately 83 percent of Newmont’s target to reduce GHG emissions intensity by 16.5 percent by the end of 2020
- Engaging with government, community and contractors to resolve a dispute at the Peñasquito operation in Mexico, which resulted in reaching a 30-year water agreement with the San Juan de Cedros community and signing a memorandum of understanding for an Investment and Social Development Plan that details Newmont’s commitments to the community
- Creating the Global Center for Indigenous Community Relations and the Advisory Council of Canadian and Indigenous Affairs to further enhance Newmont’s global approach to indigenous relations and ensure all commitments to First Nations in Canada and elsewhere are honored
The report also includes an update on Newmont’s efforts – such as protective measures at operating sites and the establishment of a $20 million fund to support communities – to help manage the impacts of the COVID-19 pandemic.
Newmont’s sustainability efforts have been recognized by several independent organizations:
- For the fifth year in a row, Newmont was named the top gold miner in the Dow Jones Sustainability World Index (DJSI)
- Newmont earned a “B” score from CDP for its 2019 Climate Change and Water Security performance
- Newmont was added to the Corporate Human Rights Benchmark’s (CHRB) 2019 evaluation and was ranked 12 th out of more than 200 companies that were assessed against the CHRB’s human rights performance criteria
- For the second consecutive year, Newmont was included in Bloomberg’s Gender-Equality Index (GEI) for its efforts to advance qualified women in the workplace
- Newmont was the top mining company in CR Magazine ’s 100 Best Corporate Citizens list and FORTUNE’s 2020 list of the World’s Most Admired Companies
- Newsweek included Newmont on its first-ever list of America’s Most Responsible Companies for 2020
To meet the needs of both investors and a broader range of stakeholders, Newmont’s 2019 Sustainability Report was written in accordance with the GRI (formerly Global Reporting Initiative) Standards Core option, including the GRI Mining and Metals Sector Supplement, and it follows the Sustainability Accounting Standards Board (SASB) Metals & Mining Sustainability Accounting Standard, the framework preferred by investors. In addition, the report’s climate change information aligns with the Task Force on Climate-related Financial Disclosures (TCFD) reporting guidelines.
Issues and metrics covered in Beyond the Mine were selected based on comprehensive engagement with Newmont employees and leadership; a specially convened panel of global opinion leaders from NGOs, academia and the investor community; and hands-on engagement and reviews with the Safety and Sustainability Committee of Newmont’s Board of Directors.
The report demonstrates Newmont’s commitment to disclosing its performance – including site-level data – on its most material sustainability topics. The full report, along with ESG data tables and a comprehensive GRI/SASB/TCFD content index, is available as a downloadable document on Newmont’s website .
About Newmont
Newmont is the world’s leading gold company and a producer of copper, silver, zinc and lead. The Company’s world-class portfolio of assets, prospects and talent is anchored in favorable mining jurisdictions in North America, South America, Australia and Africa. Newmont is the only gold producer listed in the S&P 500 Index and is widely recognized for its principled environmental, social and governance practices. The Company is an industry leader in value creation, supported by robust safety standards, superior execution and technical proficiency. Newmont was founded in 1921 and has been publicly traded since 1925.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200601005244/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
